Register entry
Ascendis Pharma, Endocrinology, Inc.
Data as of · How to read this entry
- Registered sites
- 0
- Active NDC listings
- 20
- Labeller names
- 2
- Live patents
- 0
- Countries
- 0
Catalogue
Drug listings by form and route
2020 active NDC listings: 20 human prescription drug. By marketing category: BLA 14, NDA 6.
| Dosage form | NDCs |
|---|---|
| injection, powder, lyophilized, for solution | 14 |
| injection, solution | 3 |
| kit | 3 |
| Route | NDCs |
|---|---|
| subcutaneous | 17 |
| Labeller name on the listing | NDCs |
|---|---|
| ascendis pharma endocrinology, inc. | 17 |
| ascendis pharma, endocrinology, inc. | 3 |
Catalogue
Marketed products
20| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| Skytrofa | Lonapegsomatropin-tcgd | injection, powder, lyophilized, for solution, subcutaneous | 73362-003BLA |
| Skytrofa | Lonapegsomatropin-tcgd | injection, powder, lyophilized, for solution, subcutaneous | 73362-004BLA |
| Skytrofa | Lonapegsomatropin-tcgd | injection, powder, lyophilized, for solution, subcutaneous | 73362-005BLA |
| Skytrofa | Lonapegsomatropin-tcgd | injection, powder, lyophilized, for solution, subcutaneous | 73362-006BLA |
| Skytrofa | Lonapegsomatropin-tcgd | injection, powder, lyophilized, for solution, subcutaneous | 73362-007BLA |
| Skytrofa | Lonapegsomatropin-tcgd | injection, powder, lyophilized, for solution, subcutaneous | 73362-008BLA |
| Skytrofa | Lonapegsomatropin-tcgd | injection, powder, lyophilized, for solution, subcutaneous | 73362-009BLA |
| Skytrofa | Lonapegsomatropin-tcgd | injection, powder, lyophilized, for solution, subcutaneous | 73362-010BLA |
| Skytrofa | Lonapegsomatropin-tcgd | injection, powder, lyophilized, for solution, subcutaneous | 73362-011BLA |
| Skytrofa | Lonapegsomatropin-tcgd | injection, powder, lyophilized, for solution, subcutaneous | 73362-012BLA |
| Skytrofa | Lonapegsomatropin-tcgd | injection, powder, lyophilized, for solution, subcutaneous | 73362-013BLA |
| Skytrofa | Lonapegsomatropin-tcgd | injection, powder, lyophilized, for solution, subcutaneous | 73362-014BLA |
| Skytrofa | Lonapegsomatropin-tcgd | injection, powder, lyophilized, for solution, subcutaneous | 73362-015BLA |
| Skytrofa | Lonapegsomatropin-tcgd | injection, powder, lyophilized, for solution, subcutaneous | 73362-016BLA |
| Yorvipath | Palopegteriparatide | injection, solution, subcutaneous | 73362-100NDA |
| Yorvipath | Palopegteriparatide | injection, solution, subcutaneous | 73362-101NDA |
| Yorvipath | Palopegteriparatide | injection, solution, subcutaneous | 73362-102NDA |
| Yuviwel | Navepegritide | kit | 73362-201NDA |
| Yuviwel | Navepegritide | kit | 73362-202NDA |
| Yuviwel | Navepegritide | kit | 73362-203NDA |
Enquiry
Common questions
- Is Ascendis Pharma, Endocrinology, Inc. FDA approved?
- Ascendis Pharma, Endocrinology, Inc. holds no registered establishment of its own; 20 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Ascendis Pharma, Endocrinology, Inc. make?
- 20 products are listed under Ascendis Pharma, Endocrinology, Inc. in the openFDA NDC Directory, most often as injection, powder, lyophilized, for solution; injection, solution; kit. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.